Observational study evaluating the long-term safety and efficacy of avapritinib in the first-line treatment of patients with platelet-derived growth factor receptor alpha (PDGFRA) D842V-mutated gastrointestinal stromal tumour (GIST)

ENCePP Code of conduct

Yes

Data sources

• Data sources (types):
  Electronic healthcare records (EHR)

  Other
• Data sources (types), other:
  Prospective patient-based data collection. Data will be analysed from treatment-naïve patients who will be newly enrolled into this study, and from patients who meet the eligibility criteria and already received first-line avapritinib during participation in study BLU-285-1101 or CUP/EAP.

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No

Procedures

No information provided.